Open AccessConcise review: Combining human leukocyte antigen G and mesenchymal stem cells for immunosuppressant biotherapy
Author(s) -
Naji Abderrahim,
RouasFreiss Nathalie,
Durrbach Antoine,
Carosella Edgardo D.,
Sensébé Luc,
Deschaseaux Frédéric
Publication year - 2013
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.1494
Subject(s) - mesenchymal stem cell , biology , human leukocyte antigen , immunology , immune system , transplantation , stem cell , hla g , immune tolerance , stromal cell , cancer research , antigen , microbiology and biotechnology , medicine , surgery
A bstract Both human leukocyte antigen G (HLA‐G) and multipotential mesenchymal stem/stromal cells (MSCs) exhibit immunomodulatory functions. In allogeneic tranplantation, the risks of acute and chronic rejection are still high despite improvement in immunosuppressive treatments, and the induction of a state of tolerance to alloantigens is not achieved. Immunomodulatory properties of MSCs and HLA‐G in human allogeneic tranplantation to induce tolerance appears attractive and promising. Interestingly, we and others have demonstrated that MSCs can express HLA‐G. In this review, we focus on the expression of HLA‐G by MSCs and discuss how to ensure and improve the immunomodulatory properties of MSCs by selectively targeting MSCs expressing HLA‐G (MSCs HLA‐G+ ). We also discuss the possible uses of MSCs HLA‐G+ for therapeutic purposes, notably, to overcome acute and chronic immune rejection in solid‐organ allogeneic transplantation in humans. Since MSCs are phenotypically and functionally heterogeneous, it is of primary interest to have specific markers ensuring that they have strong immunosuppressive potential and HLA‐G may be a valuable candidate. S tem C ells 2013;31:2296–2303